Tavneos (avacopan)

Buy Tavneos (avacopan)

What is Tavneos (avacopan) for?

Tavneos (avacopan) is a selective complement 5a receptor inhibitor indicated for use with other medicines (such as glucocorticoids) to treat adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) (granulomatosis with polyangiitis [GPA], formerly known as Wegener’s granulomatosis, and microscopic polyangiitis [MPA]).^[1]

It does not eliminate the need for use of glucocorticoids.^[1]

It is available in capsule form, each containing 10 mg of avacopan.^[1]

How does Tavneos (avacopan) work?

AAV is a rare autoimmune disorder in which the body’s immune system attacks small blood vessels. This causes organ damage and failure, especially the kidneys. Currently, AAV is treated with a combination of medications, including glucocorticoids, which can have toxic effects when used for prolonged periods of time.^[2]

AAV occurs when the complement pathway is activated, leading to production of the protein complement 5a (C5a). The active ingredient in Tavneos, avacopan, blocks the effects of C5a through the C5a receptor. This is expected to help reduce blood vessel inflammation and improve symptoms.^[3]

Where has Tavneos (avacopan) been approved?

Tavneos (avacopan) was approved for the treatment of AAV by:

• The Food and Drug Administration (FDA), USA on October 13, 2021.^[4]
• The European Medicines Agency (EMA) on January 11, 2022.^[5]

Tavneos (avacopan) received Orphan Drug Designation for the treatment of AAV and for C3 glomerulopathy (C3G).^[4]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Tavneos (avacopan) taken?

The standard dosage is:^[1]

• 30 mg (three 10 mg capsules) twice daily, with food.

If you miss a dose of Tavneos, do not take the missed dose. Just take the next dose at your regular time. Do not double the next dose.^[1]

Before starting with treatment, your liver function will be evaluated and you will be tested for Hepatitis B (HBV).^[1]

Do not use Tavenos together with strong and moderate CYP3A4 enzyme inducers. Reduce the to 30 mg once daily when using together with CYP3A4 inhibitors.^[1]

Complete information about Tavneos (avacopan) dosage (modifications) and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Tavneos (avacopan)?

Common adverse reactions

The most common side effects (≥5% of patients) listed in the prescribing information include:^[1]

• Nausea
• Diarrhea
• Tiredness
• Increase in blood creatinine
• Headache
• Vomiting
• Stomach pain
• Burning or prickling sensation
• High blood pressure
• Rash
• Dizziness

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:^[1]

• Liver problems (hepatotoxicity)
• Serious hypersensitivity reactions
• Hepatitis B virus (HBV) reactivation
• Serious infections

Use in a specific population

It is not known if Tavneos (avacopan) will harm your unborn baby or if it passes into your breast milk Talk to your treating doctor if you are pregnant or planning to become pregnant, or about the best way to feed your baby while taking this medicine.^[1]

Tavneos is not recommended for patients with active, untreated and/or uncontrolled chronic liver disease (e.g., hepatitis B, hepatitis C, autoimmune hepatitis) and cirrhosis. Discuss the risk and benefit with your treating doctor before starting treatment.^[1]

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Full prescribing information [FDA]: Tavneos (avacopan) [PDF]
ChemoCentryx, Oct 2021

2. What is ANCA vasculitis?
Ancavasculitisnews.com, cited Oct 2021

3. Avacopan for the Treatment of ANCA-Associated Vasculitis
Jayne DRW, et al., NEJM, Feb 2021

4. FDA approves add-on drug for adults with rare form of blood vessel inflammation
FDA press release, Oct 2021

5. Tavneos
EMA, Jan 2022